Tuttle Lausen

The developmental trajectories of soccer players’ EFs follow the general populations’ despite long-term exposure to soccer-specific training and game play. This brings into question the relationship between high-level experience and EFs and renders including EFs in talent identification questionable.Social interactions are theorized to inform…[Read more]

The developmental trajectories of soccer players’ EFs follow the general populations’ despite long-term exposure to soccer-specific training and game play. This brings into question the relationship between high-level experience and EFs and renders including EFs in talent identification questionable.Social interactions are theorized to inform…[Read more]

Background and objective Dengue viral infections are a standout amongst the supreme critical mosquito-borne illnesses nowadays. They create problems like dengue fever (DF), dengue stun disorder (DSS) and dengue hemorrhagic fever (DHF). Lately, the frequency of DHF has expanded considerably. Dengue may be caused by one of serotypes DEN-1 to DEN-4.…[Read more]

Ibrutinib is a BTK/ITK inhibitor with efficacy for the treatment of various lymphoid cancers, including CLL. Considering that innate and adaptative immune defects are a dominant feature of CLL patients, we evaluated whether in vitro ibrutinib affects the survival and function of neutrophils and γδ T cells, key players of the early immune r…[Read more]

Ibrutinib is a BTK/ITK inhibitor with efficacy for the treatment of various lymphoid cancers, including CLL. Considering that innate and adaptative immune defects are a dominant feature of CLL patients, we evaluated whether in vitro ibrutinib affects the survival and function of neutrophils and γδ T cells, key players of the early immune r…[Read more]

Ibrutinib is a BTK/ITK inhibitor with efficacy for the treatment of various lymphoid cancers, including CLL. Considering that innate and adaptative immune defects are a dominant feature of CLL patients, we evaluated whether in vitro ibrutinib affects the survival and function of neutrophils and γδ T cells, key players of the early immune r…[Read more]

Ibrutinib is a BTK/ITK inhibitor with efficacy for the treatment of various lymphoid cancers, including CLL. Considering that innate and adaptative immune defects are a dominant feature of CLL patients, we evaluated whether in vitro ibrutinib affects the survival and function of neutrophils and γδ T cells, key players of the early immune r…[Read more]